Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences

Journal of Medical Virology

Volumn 79, Issue 11, 2007, Pages 1664-1670

  Enomoto, Masaru ^a   Tamori, Akihiro ^a   Kohmoto, Madoka Toyama ^a   Morikawa, Hiroyasu ^a   Habu, Daiki ^a   Sakaguchi, Hiroki ^a   Takeda, Tadashi ^a   Seki, Shuichi ^a   Kawada, Norifumi ^a,c   Shiomi, Susumu ^a   Nishiguchi, Shuhei ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c NONE   (Japan)

Author keywords

Chronic HBV; HBV mutational patterns; HBV polymerase gene; Lamivudine; YMDD variants

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTIC ACID; ISOLEUCINE; LAMIVUDINE; METHIONINE; TYROSINE; VALINE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; STRUCTURAL GENE; VIRUS GENOME; VIRUS MUTATION;

ADULT; AGED; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOME, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; JAPAN; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 34748844767     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20984     Document Type: Article

References (36)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD, 1998. Identification and cbaracterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group Hepatology 27:1670-1677.
2. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T, 2001. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 358:718-723.
3. Bock CT, Kubicka S, Manns MP, Trautwein C. 1999. Two control elements in the hepatitis B virus S-promoter are important for full promoter activity mediated by CCAAT-binding factor. Hepatology 29:1236-1247.
4. Carman WF. 1997. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4:11-20.
5. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. 1989. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2:588-591.
6. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE IV, Isom H, Bowden S, Desmond P, Locarnini SA. 2003. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27-35.
7. Delaney WE IV, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833-11841.
8. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading, and staging. Hepatology 19:1513-1520.
9. Ehata T, Omata M, Chuang WL, Yokosuka O, Ito Y, Hosoda K, Ohto M. 1993. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Cllin Invest 91: 1206-1213.
10. Enomoto M, Nishiguchi S, Seki S, Yamane T, Hino M. 2004. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma. Am J Gastroenterol 99:1619-1620.
11. Ganem D, Prince AM. 2004. Hepatitis B virus infection - Natural history and clinical consequences. N Engl J Med 350:1118-1129.
12. Gerken G, Gomes J, Lampertico P, Colombo M, Rothaar T, Trippler M, Colucci G, 1998. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods 74:155-165.
13. Gunther S, Baginski S, Kissel H, Reinke P, Kruger DH, Will H, Meisel H, 1996. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology 24:751-758.
14. Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S, 1999. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 37:310-314.
15. Kobayashi M, Koike K. 1984. Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene 30:227-232.
16. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, Sakaguchi H, Seki S, Shiomi S, Nishiguchi S. 2005. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 75:235-239.
17. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group N Engl J Med 339:61-68.
18. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group Gastroenterology 119:172-180.
19. Liu CJ, Chen PJ, Lai MY, Kao JH, Chang CF, Wu HL, Shau WY, Chen DS, 2003. A prospective study characterizing full-length hepatitisB virus genomes during acute exacerbation. Gastroenterology 124: 80-90.
20. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, Pawlotsky JM, Zoulim F. 2004. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9:679-693.
21. Lok AS, Akarca U, Greene S. 1994. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenome encapsidation signal. Proc Natl Acad Sci USA 91:4077-4081.
22. Mizokami M, Nakano T, Orito E, Tanaka Y, Sakugawa H, Mukaide M, Robertson BH. 1999. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 450:66-71.
23. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. 1999. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 59:270-276.
24. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. 1994. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 68:8102-8110.
25. Okamoto H, Tsuda F, Mayumi M. 1987. Defective mutants of hepatitis B virus in the circulation of symptom-free carriers. Jpn J Exp Med 57:217-221.
26. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. 1991. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 324:1699-1704.
27. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449-455.
28. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
29. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S. 2001. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group Hepatology 33:218-223.
30. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R, AI463026 BEHoLD Study Group. 2006. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130:2039-2049.
31. Sterneck M, Gunther S, Santantonio T, Fischer L, Broelsch CE, Greten H, Will H. 1996. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology 24:300-306.
32. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. 2000. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 38:702-707.
33. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF, 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
34. Takahashi K, Akahane Y, Hino K, Ohta Y, Mishiro S. 1998. Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: Comparative analysis of 40 full-length isolates. Arch Virol 143:2313-2326.
35. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M. 1999. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 80:97-112.
36. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312-323.